Intravenous Immunoglobulin Market

Market Overview

The global intravenous immunoglobulin market size was valued at USD 11.17 billion in 2021. It is projected to reach USD 21.06 billion by 2030, growing at a CAGR of 7.3% during the forecast period (2022–2030).

The antibodies produced by the immune system naturally to help fight disease and infection are known as immunoglobulins. IVIG, also known as intravenous immunoglobulin, is a treatment that combines immunoglobulins donated by various individuals to treat a variety of conditions. It is administered intravenously or through a drip. Plasma is used to create IVIG and other immunoglobulins. IVIG is used to lessen the effects of some inflammatory immune-system-related diseases, also referred to as autoimmune diseases. Additionally, it is used to raise immunoglobulin levels that are low or that have fallen because of taking other medications, like rituximab.

Market Dynamics

Global Intravenous Immunoglobulin Market Drivers

Rising Use of Intravenous Immunoglobulin (IVIG) Therapies

The global IVIG market is expanding rapidly due to the rising number of patients with bleeding disorders and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sufferers. In addition, rising investment in the healthcare business also contributes to the IVIG market's expansion. The increasing number of patients with autoimmune diseases and other pathological disorders is driving the expansion of the IVIG market. Furthermore, sedentary lifestyle habits, such as eating saturated fats, salt, and sweets, decreased physical activity, and excessive alcohol use, have contributed to the prevalence of these diseases.

Growing Prevalence of Primary Immunodeficiency Disorders

According to indication, the global intravenous immunoglobulin market has been segmented into the following groups:

• Guillain-Barre syndrome
• Myasthenia gravis
• Idiopathic thrombocytopenic purpura (ITP)
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Primary humoral immunodeficiency
• Guillain-Barre syndrome
• Multifocal motor neuropathy
• Chronic inflammatory demyelinating polymer

The hypogammaglobinemia market category is the most significant, which can be explained by the growth in the prevalence of primary immunodeficiency diseases (PID) worldwide. Patients diagnosed with lymphoproliferative disorders have a significantly increased risk of developing this sort of persistent immune impairment (LPDs).

Global Intravenous Immunoglobulin Market Restraints

Growing Price of IVIG Treatment

It is anticipated that the steadily increasing price of IVIG therapy will constitute a significant barrier to market expansion. Immunoglobulin Infusions are usually administered once every three to four weeks, and the therapy typically consists of 12 to 16 sessions per year. The intravenous immunoglobulin G (IVIG) treatment costs USD 73.89 per gram, ranging from USD 7,000 to 10,000. Immunoglobulin replacement therapies are long-term treatments that typically last six months. According to the ABIM Foundation, the annual cost of IgG treatment therapy is more than USD 30,000.

Global Intravenous Immunoglobulin Market Opportunities

Growing Research and Development

Increased immunoglobulin usage, increased frequency of new releases, and rapid clearance from government regulatory agencies worldwide are expected to fuel demand for immunoglobulin. In addition, the increase in government initiatives promoting the intravenous administration of certain pharmaceuticals drives the global market. For example, the Ministry of Health and Family Welfare of Karnataka decided to purchase an intravenous immunoglobulin (IVIG) medication for emergency use among children in June 2021.

Regional Analysis

The global intravenous immunoglobulin market is segmented into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

North America is the most significant shareholder in the global intravenous immunoglobulin market. The critical factors leading to the market's growth are the increasing degree of awareness regarding goods used to treat immunodeficiency illnesses, the rising predisposition of doctors towards these therapies, and the rising healthcare expenditure. Additional factors anticipated to support the expansion of the regional market include the rising use of IVIG therapies for the treatment of disease, the presence of well-established healthcare and research infrastructure, and the rapidly rising number of product approvals from the U.S. FDA. In addition, the rising prevalence of PID is anticipated to create future growth possibilities for this market. Autoimmune diseases are the third most prevalent cause of chronic illness in the United States. Due to the rarity of many autoimmune conditions, the National Institutes of Health estimate that 5-8% of the U.S. population is affected. Autoimmune disorders are growing more widespread for unexplained causes and are anticipated to increase during the forecast period.

The Asia-Pacific region is anticipated to experience lucrative growth during the forecast period due to the growing awareness of and potential opportunities for adopting immunoglobulin-based therapies to treat primary immune deficiencies and the growing geriatric population. Additionally, future growth is anticipated to be fueled by the rising incidence of immunological diseases, increased knowledge of intravenous and subcutaneous immunoglobulin therapy, and improved healthcare infrastructure.

Segmental Analysis

The global intravenous immunoglobulin market is segmented by application and distribution channel.

On the Basis of Application

Based on application, the market is divided into Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, and Guillain-Barre Syndrome.

The immunodeficiency segment led the global intravenous immunoglobulin market due to the increasing prevalence of primary and acquired immunodeficiency illnesses. To eliminate the infections, PID and AIDS are treated with intravenous antibiotics. IVIG replacement therapy is the most excellent treatment option available for immunodeficiency illnesses. The chronic inflammatory demyelinating polyneuropathy sector held the second-largest share and is typically treated with immunosuppressive medications, corticosteroids, and plasmapheresis. IVIG provides a long-lasting and effective alternative to these treatments. The accompanying advantages, such as safety, minimally invasiveness, and user-friendliness, contribute to the sector's expansion. Hypogammaglobulinemia holds the third-largest revenue share due to the increasing prevalence of primary immunodeficiency disorders (PID) worldwide. It is the most prevalent chronic immunological deficiency in lymphoproliferative disease patients (LPDs).

On the Basis of Distribution Channel

Based on the distribution channel, the market is divided into hospital pharmacy and specialty pharmacy.

The hospital pharmacy segment dominates the market with the highest revenue share due to the extensive network of hospitals and the wide variety of items readily available through hospital pharmacies. In addition, the rising prevalence of primary immunological deficiencies, hepatitis C, and other disorders have increased hospitalizations worldwide, increasing customers' desire for hospital pharmacies. In addition, hospitals offer prompt reimbursement, treatment, and proper care to many patients, increasing the number of patients choosing hospital pharmacies. As specialty pharmacies facilitate at-home therapy, the specialty pharmacy market is predicted to expand significantly during the forecast period. Specialty medications are a vital and dynamic component of the pharmacy industry. Consequently, the number of licensed specialty pharmaceuticals is overgrowing, propelling the specialty pharmacy market during the projection period.

Recent Developments

• June 2022- Baxter Issues Urgent Medical Device Correction to Reinforce Important Safety Information Regarding Possible Risk of Oxygen Desaturation While Using Volara Device in Line with Ventilator in a Home Care Environment.
• June 2022- Biotest AG: Biotest achieves an essential milestone in the Phase III study in acquired fibrinogen deficiency.
• May 2022- FDA Accepts CSL Behring’s Biologics License Application for Etranacogene Dezaparvovec for Priority Review.
• April 2022- Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation.